FDA Seeks Panel Feedback On Lung Tumor, Emphysema Device Applications
This article was originally published in The Gray Sheet
Executive Summary
Clinical data necessary to support the use of ablation devices for local control of unresectable malignant primary and metastatic lung tumors will be discussed by FDA's General & Plastic Surgery Devices Advisory Panel Feb. 28 in Gaithersburg, Md
You may also be interested in...
Artes Medical Wrinkle Treatment PMA Slated For Panel Review Feb. 28
Artes Medical's injectable polymeric microspheres technology permanently treats deep facial wrinkles by stimulating tissue augmentation, the company says
RITA Medical Expects Revenue Of $21 Mil. In 2002, Profitability By Q4
RITA Medical Systems anticipates sales of $21-23 mil. in 2002, driven by StarBurst radiofrequency ablation product launches for lung and bone indications
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”